StockPreacher.com Issues Trading Outlook for Generex Biotechnology Corp.

• Press Release
• Source: StockPreacher
• On 6:50 am EDT, Wednesday September 30, 2009

DALLAS, Sept. 30, 2009 (GLOBE NEWSWIRE) -- StockPreacher.com announces an investment report featuring biopharmaceutical company Generex Biotechnology Corp. (Nasdaq:GNBT - News). The report includes financial and investment analysis, analyst consensus, and pertinent industry information you need to know to make an educated investment decision.

Related Quotes

Symbol	Price	Change
BVF	14.52	0.00

{"s" : "bvf,eln,gnbt,mnkd,nvo","k" : "c10,l10,p20,t10","o" : "","j" : ""}

The investment report on Generex Biotechnology Corp. (Nasdaq:GNBT - News) should be of particular interest to comparable companies: MannKind Corp. (Nasdaq:MNKD - News), Novo Nordisk A/S (NYSE:NVO - News), Elan Corp. (NYSE:ELN - News) and Biovail Corp. (NYSE:BVF - News).

The full report is available at: http://www.stockpreacher.com/n/GNBT

Get our alerts BEFORE the rest of the market. Follow us on Twitter: http://twitter.com/StockPreacher

Generex Biotechnology Corp. (GNBT) engages in the development, research and commercialization of drug delivery systems and technologies for metabolic and immunological diseases. It has developed its flagship product Oral-lyn, an oral insulin spray that allows the drug to be absorbed through the inside lining of the cheeks, enabling diabetics to avoid the potential risks of chronic lung tissue exposure associated with other forms of inhaled insulin. Oral-lyn has been approved for use in India, Algeria, Lebanon and Ecuador, though in the U.S. it is still undergoing clinical trials.

Message Board Search for RZ: http://www.boardcentral.com/boards/GNBT

In the report, the analyst notes:

"Though Oral-lyn has been granted approval in some developing countries, it is still undergoing clinical trials in the U.S., and patient selection commenced last year. On September 10, GNBT announced a major step forward for its flagship buccal insulin product when the U.S. Food and Drug Administration (FDA) granted approval for the treatment use of Generex Oral-lyn under the FDA's Treatment Investigational New Drug (IND) program.

"Extending its international reach, the Company recently announced that its Generex Biotechnology Corp. MENA branch office has begun implementing distribution networks outside of the Middle East and North Africa...In the U.S., GNBT also expects to increase market opportunities through implementation of media campaign. Targeting the New York, New Jersey, Houston and Dallas market, the Company recently launched radio ads, with television advertising in major markets to follow."

To read the entire report visit: http://www.stockpreacher.com/n/GNBT

StockPreacher.com is a small-cap research and investment commentary provider. StockPreacher.com strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on StockPreacher, please visit: http://www.stockpreacher.com

StockPreacher.com Disclosure

StockPreacher.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. StockPreacher.com is a Web site wholly-owned by BlueWave Advisors, LLC. Please read our report and visit our Web site, StockPreacher.com, for complete risks and disclosures.

StockPreacher.com
Jeff Bishop
(469)-252-3505
press@beaconequity.com